X-ZELL outperforms traditional immunostaining in German landmark study Leipzig, July 2024 – New research from Germany has shown that X-ZELL technology could dramatically reduce the number of inconclusive cancer diagnoses from minimally invasive sample material. During...
X-ZELL launches Global Technology Trial Leipzig, June 2024 –To celebrate the 45th anniversary of the European Congress of Cytology (ECC) in Leipzig, Germany, X-ZELL has launched the company’s inaugural Global Technology Trial. X-ZELL Founder & CEO, Dr Sebastian...
X-ZELL technology now IVDR-compliant and FDA-listed Singapore, March 2024 – X-ZELL is proud to announce that the company’s ground-breaking Next-Generation Cytology (NGC) technology is now officially available for routine use in Europe and the US. X-ZELL NGC is a...
X-ZELL Live Experience Tour wrapped Singapore, November 2023 – X-ZELL’s first global conference tour has officially wrapped after the series’ final instalment at the Annual Scientific Meeting of the American Society of Cytopathology (ASC) in Austin, Texas, USA. Aimed...
X-ZELL enabling same-day diagnoses at German routine laboratory Budapest, October 2023 – New research has shown that X-ZELL Cryoimmunostaining™ is able to facilitate same-day cancer diagnoses from minimally invasive samples in routine clinical practice PD Dr. med....
X-ZELL technology used in development of new T cell therapy Singapore, September 2023 – A research team at Duke-NUS Medical School in Singapore has developed a T cell therapy that could play an important role in treating cancer recurrences after liver transplants. The...
